Please enable JavaScript.
Coggle requires JavaScript to display documents.
FMI Business Challenges - Coggle Diagram
FMI Business Challenges
1. Low CGP recognition
Regard CGP value is low
Don't Know/ fully understand/ buying
Difficult
No place/ no one to learn from
Too new
No guidence
Cannot catch up
Too much information
Too busy
Limited experience
Bad experience
No after support
Delay
No variant
Qualified report
Don't know how to manage difficult/complicated cases
Follow current treatment guidelines
No one ever to him
Not enough benefit to HCPs
No incentive
Troublesome
Off-label management
Effort to explain
Not enough benefits to patients
Economic burden
Low income
Not affordable
Off-label treatment is not reimbursed
No desirable results
No variants
Only limited mutations
Enough reimbursement treatments
Limited Liquid Endorsement
Not confident in liquid-based genomic profiling
Tissue is main stream
No good experience
No variants
Too many unreliable liquid companies
Not enough clinical evidence
Not updated to technology advancement
Not comprehensive enough
Panel size
Amplifications
Non-shedders
No Clear Consensus in CGP Use
3. Dynamix and competitive market landscape
Ideology or longterm Partnership
Flexible price offering
Response to customer needs
Competitors' strong SoV
2. Limited Access
Regulatory requirements
Referral model to listing
Off-shore barriers
No DTC
Reimbursement
Self-pay